We got here throughout a bullish thesis on McKesson Company on The Buyside Man’s Substack. On this article, we’ll summarize the bulls’ thesis on MCK. McKesson Company’s share was buying and selling at $710.94 as of August 4th. MCK’s trailing and ahead P/E have been 27.17 and 18.69, respectively in response to Yahoo Finance.
A profitable pharmacist in entrance of cabinets of medicine in a community-based oncology pharmacy.
McKesson (MCK) is likely one of the largest pharmaceutical distributors within the U.S., transferring practically a 3rd of all pharmaceuticals throughout North America and controlling 38.1% of the U.S. distribution market alongside AmerisourceBergen and Cardinal Well being. Performing because the infrastructure layer of the healthcare system, McKesson supplies logistics, stock administration, credit score danger dealing with, and compliance, working on razor-thin margins that make the enterprise extremely defensible and practically not possible for brand new entrants.
Even retail giants like CVS and Walgreens rely on its effectivity, with most pharmacy orders fulfilled inside 24 hours. Its moat lies in compliance—McKesson should meet stringent DEA and DSCSA necessities, monitoring each tablet via the availability chain, which creates vital obstacles to entry and buyer stickiness. The enterprise mannequin is secure: branded medicine generate mounted charges per unit, insulating earnings from worth swings, whereas generics—although decrease income—ship greater margins and account for about 29% of working revenue. Buyer focus is notable, with CVS and Walmart collectively contributing roughly 14% of working earnings.
Whereas McKesson trades defensively throughout market volatility, short-term earnings misses can stress the inventory. A key catalyst is the deliberate spin-off of its Medical-Surgical section, which has greater margins (8–10%) however provides volatility; separation might unlock valuation readability and upside. At the moment, McKesson trades at 17.8x FY’26 EPS, above its 10-year common of ~14.5x, reflecting sturdy fundamentals like a 17% five-year EPS CAGR and seven% buyback CAGR. Although not low-cost as we speak, a pullback to $550–$600 might provide a horny entry level into this important, scale-driven enterprise.
Beforehand, we lined a bullish thesis on Quipt Residence Medical Corp. (QIPT) by Inflexio Analysis in March 2025, which highlighted its recurring income base, activist involvement, and buyout potential. The inventory has appreciated about 4.78% since then as restoration indicators emerged. The thesis nonetheless stands with strategic catalysts intact. The Buyside Man shares the same view on defensiveness however emphasizes McKesson’s scale, compliance moat, and Med-Surg spin-off catalyst.